Erratum: A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in latino patients (Digestive Diseases and Sciences DOI: 10.1007/s10620-009-1062-3);A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients

Digestive Diseases and Sciences

Volumn 55, Issue 9, 2010, Pages 2629-2635

  Méndez Navarro, Jorge ^a,b   Chirino, Ruby A ^a   Corey, Kathleen E ^b   Gorospe, Emmanuel C ^c   Zheng, Hui ^d   Morán, Segundo ^a   Chung, Raymond T ^b   Dehesa Violante, Margarita ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Amantadine; Chronic hepatitis C; Latino; Peginterferon; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRY SKIN; FATIGUE; FEMALE; FLU LIKE SYNDROME; FORNS INDEX; GENOTYPE; HEADACHE; HEPATITIS C; HISPANIC; HUMAN; KNODELL INDEX; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77956188601     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1114-8     Document Type: Erratum

References (39)

1. BP Bell M Manos A Zaman, et al. 2008 The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance Am J Gastroenterol 103 2727 2736 10.1111/j.1572-0241.2008.02071.x 18684170
2. JL Valdespino CJ Conde-Gonzalez G Olaiz-Fernandez O Palma D Kershenobich J Sepulveda 2007 Seroprevalencia de la hepatitis C en Adultos de México: Un problema de salud publica emergente? Salud Pública de México 49 S395 S403
3. JF Sanchez-Avila E Gonzalez V Vazquez S Suarez M Uribe 2007 Geographical distribution of HCV genotypes in Mexico Ann Hepatol 6 156 160 17786141
4. L Vera de leon JA Juarez-Navarro J Mendez-Navarro, et al. 2005 Epidemiologic and situational panorama of hepatitis C in Mexico Rev Gastroenterol Mex 70 25 32 16170959
5. M Dehesa-Violante F Bosques-Padilla D Kershenobich 2007 Prevalence of hepatitis C virus genotypes in Mexican patients Rev Gastroenterol Mex 72 344 348 18595321
6. AM Rivas-Estilla P Cordero-Perez L Muñoz-Espinosa, et al. 2008 Genotyping of hepatitis C virus (HCV) in infected patients from northeast Mexico Ann Hepatol 7 144 147 1:CAS:528:DC%2BD1cXhtlOgsbbO 18626432
7. J Dienstag JG McHutchison 2006 American Gastroenterological Association technical review on the management of hepatitis C Gastroenterology 130 231 264 10.1053/j.gastro.2005.11.010 16401486 (Pubitemid 43049856)
8. K Weigand W Stremmel J Encke 2007 Treatment of hepatitis C virus infection World J Gastroenterol 13 1897 1905 1:CAS:528:DC%2BD2sXmsFOnsLw%3D 17461488
9. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 958 965 10.1016/S0140-6736(01)06102-5 1:CAS:528:DC%2BD3MXntF2qtb8%3D 11583749 (Pubitemid 32913521)
10. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa 2a plus ribavirin for chronic hepatitis c virus infection N Engl J Med 347 975 982 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D 12324553
11. M Hepburn L Hepburn N Cantu M Lapeer E Lawitz 2004 Differences in treatment outcome for hepatitis C among ethnic groups Am J Med 117 163 168 10.1016/j.amjmed.2004.02.043 1:CAS:528:DC%2BD2cXmtVWitro%3D 15276594
12. M Rodriguez-Torres 2008 Latinos and chronic hepatitis C: a singular population Clin Gastroenterol Hepatol 6 484 490 10.1016/j.cgh.2008.02.036 18455693 (Pubitemid 351609457)
13. M Rodriguez-Torres L Jeffers M Sheikh, et al. 2009 Peginterferon Alfa-2a and ribavirin in Latino and non-Latino whites with Hepatitis C N Engl J Med 360 257 267 10.1056/NEJMoa0805062 1:CAS:528:DC%2BD1MXnsFGitA%3D%3D 19144941
14. J McHutchison K Patel 2002 Future therapy of hepatitis C Hepatology 36 S245 S252 10.1002/hep.1840360731 12407600
15. D Clarke S Griffin L Beales, et al. 2006 Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus P7 protein in vitro J Biol Chem 281 37057 37068 10.1074/jbc.M602434200 1:CAS:528:DC%2BD28Xht1elt77L 17032656 (Pubitemid 46042176)
16. S Griffin C St. Gelais A Owsianka AH Patel D Rowlands M Harris 2008 Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 Ion channel Hepatology 48 1779 1790 10.1002/hep.22555 1:CAS:528:DC%2BD1cXhsFamsrfN 18828153
17. E Steinmann T Whitfield S Kallis, et al. 2007 Antiviral effects of amantadine and iminosugar derivates against hepatitis C virus Hepatology 46 330 338 10.1002/hep.21686 1:CAS:528:DC%2BD2sXhtVSisb7K 17599777 (Pubitemid 47344767)
18. J Gottwein T Scheel T Jensen, et al. 2009 Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type 1 and effect of antiviral drugs Hepatology 49 364 377 10.1002/hep.22673 1:CAS:528:DC%2BD1MXivFWhsbc%3D 19148942
19. T Berg B Kronenberger H Hinrichsen, et al. 2003 Triple therapy with amantadine in treatment-naïve patients with chronic hepatitis C: a placebo controlled trial Hepatology 37 1359 1367 10.1053/jhep.2003.50219 1:CAS:528:DC%2BD3sXkvFWltbo%3D 12774015 (Pubitemid 36667316)
20. P Deltenre J Henrion V Canva, et al. 2004 Evaluation of amantadine in chronic hepatitis C: a meta-analysis J Hepatol 41 462 473 10.1016/j.jhep.2004. 05.019 1:CAS:528:DC%2BD2cXntV2hurY%3D 15336450 (Pubitemid 39161910)
21. A Mangia N Minerva M Annese, et al. 2001 A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C Hepatology 33 989 993 10.1053/jhep.2001.23537 1:CAS:528: DC%2BD3MXivVGqsLY%3D 11283865 (Pubitemid 32246650)
22. H Uyama H Nakamura E Hayashi, et al. 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C Hepatol Res 37 325 330 10.1111/j.1872-034X.2007.00044.x 1:CAS:528:DC%2BD2sXmtlSmsL4%3D 17441804 (Pubitemid 46605416)
23. M Angelico B Koehler-Host P Piccolo, et al. 2008 Peginterferon α-2a and ribavirin versus peginterferon α -2 a monotherapy in early virological responders and peginterferon α-2a and Ribavirin versus peginterferon α-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C Eur J Gastroenterol Hepatol 20 680 687 10.1097/MEG. 0b013e3282f5196c 1:CAS:528:DC%2BD1cXotFags74%3D 18679072
24. Z Younossi A McCullough D Barnes, et al. 2005 Pegylated interferon α 2 b, ribavirin and amantadine for the chronic hepatitis C Dig Dis Sci 50 970 975 10.1007/s10620-005-2673-y 1:CAS:528:DC%2BD2MXjvVCnurg%3D 15906777 (Pubitemid 40691205)
25. M Angelico M Cepparulo F Angelico, et al. 2004 A randomized controlled trial of amantadine plus interferon α-2a vs. interferon α-2a alone in naïve patients with chronic hepatitis C randomized according to the early virological response to interferon α-2a monotherapy Aliment Pharmacol Ther 19 339 347 10.1111/j.1365-2036.2004.01843.x 1:CAS:528: DC%2BD2cXisVWhsrY%3D 14984381 (Pubitemid 38253509)
26. P Ferenci E Formann H Laferl, et al. 2006 Randomized, double-blind, placebo-controlled study of peginterferon alfa -2a (40 KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection J Hepatol 44 275 282 10.1016/j.jhep.2005.09.015 1:CAS:528:DC%2BD28Xktl2qsw%3D%3D 16338019 (Pubitemid 43069208)
27. M von Wagner WP Hofmann G Teuber, et al. 2008 Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa 2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection Hepatology 48 1404 1411 10.1002/hep.22483
28. S Brillanti F Levantesi L Masi M Foli L Bolondi 2000 Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C Hepatology 32 630 634 10.1053/jhep.2000.16235 1:CAS:528: DC%2BD3cXmsF2mu7g%3D 10960460
29. RG Knodell KG Ishak WC Black, et al. 1981 Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 431 435 10.1002/hep.1840010511 1:STN:280:DyaL38%2FnsVagsA%3D%3D 7308988
30. CT Wai J Greenson RJ Fontana, et al. 2003 A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 518 526 10.1053/jhep.2003.50346 12883497 (Pubitemid 36919874)
31. X Forns S Ampurdanes, et al. 2002 Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model Hepatology 36 986 992 12297848
32. MG Ghany D Strader D Thomas LB Seeff 2009 Diagnosis, management and treatment of hepatitis C: an update Hepatology 49 1335 1374 10.1002/hep.22759 1:CAS:528:DC%2BD1MXkslWjs7o%3D 19330875
33. SJ Hadziyannis H Sette TR Morgan, et al. 2004 Peginterferon alfa 2a (40 KD) plus ribavirin in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose Ann Intern Med 140 346 355 1:CAS:528:DC%2BD2cXitlOktrg%3D 14996676
34. HS Conjeevaram MW Fried LJ Jeffers, et al. 2006 Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 470 477 10.1053/j.gastro.2006.06.008 1:CAS:528:DC%2BD28XpsFyksL4%3D 16890601 (Pubitemid 44142464)
35. RC Cheung S Currie H Shen, et al. 2005 Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance and outcomes Am J Gastroenterol 100 2186 2193 10.1111/j.1572-0241.2005.00240.x 16181367
36. AW Tai RT Chung 2009 Treatment failure in Hepatitis C: mechanisms of non-response J Hepatol 50 412 420 10.1016/j.jhep.2008.11.010 1:CAS:528:DC%2BD1MXntVGgtA%3D%3D 19070928
37. JH Hoofnagle AS Wahed RS Brown CD Howell SH Belle The Virahep-C Study group 2009 Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 Infection JID 199 1112 1120 10.1086/597384 1:CAS:528:DC%2BD1MXltVOmsrs%3D 19284286
38. D Ge J Fellay A Thompson, et al. 2009 Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399 401 10.1038/nature08309 1:CAS:528:DC%2BD1MXpvFCrtbw%3D 19684573
39. M Romero-Gomez M Viloria RJ Andrade, et al. 2005 Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 636 641 10.1053/j.gastro.2004.12.049 1:CAS:528:DC%2BD2MXivFWntL8%3D 15765399 (Pubitemid 40585366)